Vaitukaitis J L
Ann Clin Lab Sci. 1974 Jul-Aug;4(4):276-80.
Ectopic production and secretion of hormones by a wide variety of tumors has been known for decades. Initially, ectopic hormone secretion was recognized by signs and symptoms of excess circulating biologically active hormone. With development of more sophisticated assay techniques, biologically inactive fragments and "big" forms of authentic hormones have been identified in these syndromes. Recently, a specific hCG assay has been developed for selectively measuring hCG in plasma samples containing both hLH and hCG. Studies reported to date suggest that hCG may be a good tumor marker. Using that assay system, several hundred sera obtained from patients with a wide variety of tumors were screened. Patients with tumors of the stomach, liver, ovary and testis were found to have the highest incidence of ectopic hCG secretion.
几十年来,人们已经知道多种肿瘤会异位产生和分泌激素。最初,异位激素分泌是通过循环中生物活性激素过量的体征和症状来识别的。随着更精密检测技术的发展,在这些综合征中已鉴定出生物无活性片段和真实激素的“大”形式。最近,已开发出一种特异性人绒毛膜促性腺激素(hCG)检测方法,用于在同时含有促黄体生成素(hLH)和hCG的血浆样本中选择性测量hCG。迄今为止报道的研究表明,hCG可能是一种良好的肿瘤标志物。使用该检测系统,对从患有多种肿瘤的患者中获得的数百份血清进行了筛查。发现患有胃、肝、卵巢和睾丸肿瘤的患者异位hCG分泌的发生率最高。